New triple therapy shows promise for hard-to-treat liver cancer
NCT ID NCT07610551
First seen May 30, 2026 · Last updated Jun 16, 2026 · Updated 3 times
Summary
This study looks at how well a three-drug combination works for people with liver cancer that cannot be removed by surgery. The treatment includes internal radiation (SIRT-Y90), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab). Researchers will track tumor shrinkage and side effects in 50 adults across eight hospitals in China.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 777, Xitai Road, Chang'an District, Xi'an City, Shaanxi Province, China
RECRUITINGXi’an, Shanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.